MicroPort CardioFlow expands heart disease portfolio with landmark acquisition

MicroPort CardioFlow Medtech Corporation has successfully completed its very substantial acquisition and connected transaction involving the issuance of new shares under a specific mandate. The transaction, completed on December 19, 2025, sees MicroPort Cardiac Rhythm Management Limited and its subsidiaries become indirect subsidiaries of MicroPort CardioFlow. This strategic move expands the group's business from interventional treatment of structural heart diseases to include cardiac rhythm management, establishing a diversified product platform in the Total Cardio field.

As a result of the acquisition, MicroPort CardioFlow issued 3,953,847,407 new ordinary shares at an issue price of HK$1.35 per share. The company's total issued shares increased from 2,412,706,775 to 6,366,554,182 ordinary shares as of December 19, 2025. This change represents a 164% increase in issued shares compared to the opening balance on November 30, 2025.

The shareholding structure has been significantly altered, with MicroPort International's stake increasing from 1,112,855,680 shares (46.12%) to 2,829,741,451 shares (44.45%). The original shareholders of the target company (excluding mentioned individuals) now hold 2,218,518,496 shares, representing 34.85% of the enlarged share capital. The company affirms that all conditions for listing and legal requirements for the share issuance have been met.